COMMUNIQUÉS West-GlobeNewswire

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
12/03/2024
BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, [...]
Philips and AWS collaborate to scale digital pathology in the cloud, enhancing diagnostic capabilities and improving productivity
12/03/2024
March 12, 2024 Cloud offering will help improve workflow integration, access, and reliability, delivering greater productivity and collaboration Collaboration combines best of clinical workflow leadership with scalable [...]
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
12/03/2024
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology [...]
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
12/03/2024
SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it received AUD $11, [...]
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12/03/2024
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Clinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non- [...]
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
12/03/2024
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and [...]
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
12/03/2024
Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second half of 2024 In Japan [...]
SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
12/03/2024
HUMMELSTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment [...]
electroCore to Participate in Upcoming Investor Conferences
12/03/2024
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy Officer, Joshua Lev [...]
SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement
12/03/2024
The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the Narayana Institute of Cardiac Sciences in Bengaluru, India FORT LAUDERDALE, Fla., March 12 [...]
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
12/03/2024
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. [...]
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
12/03/2024
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting [...]
Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System
12/03/2024
In the past six months, the Company has announced over $149 million of non-dilutive financing from the US Government for the DeepView™ Wound Imaging System DALLAS, March 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
12/03/2024
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (“USPTO”) has allowed [...]
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
12/03/2024
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD risk equivalents [...]
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
12/03/2024
—Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients— —ENLIGHTEN-Cirrhosis, the second trial in the program [...]
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
12/03/2024
Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study on track to commence in [...]
Aileron Therapeutics Announces CEO Transition
12/03/2024
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan [...]
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
12/03/2024
Former Chairman, CEO and Founder of ChemoCentryx, Inc. CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize [...]

Pages